↓ Skip to main content

Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options

Overview of attention for article published in Supportive Care in Cancer, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
6 X users
patent
9 patents
facebook
1 Facebook page

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
99 Mendeley
Title
Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options
Published in
Supportive Care in Cancer, November 2015
DOI 10.1007/s00520-015-3001-5
Pubmed ID
Authors

Janine M. Lombard, Nicholas Zdenkowski, Kathy Wells, Corinna Beckmore, Linda Reaby, John F. Forbes, Jacquie Chirgwin

Abstract

Aromatase inhibitor induced musculoskeletal syndrome is experienced by approximately half of women taking aromatase inhibitors, impairing quality of life and leading some to discontinue treatment. Evidence for effective treatments is lacking. We aimed to understand the manifestations and impact of this syndrome in the Australian breast cancer community, and strategies used for its management. A survey invitation was sent to 2390 members of the Breast Cancer Network Australia Review and Survey Group in April 2014. The online questionnaire included 45 questions covering demographics, aromatase inhibitor use, clinical manifestations and risk factors for the aromatase inhibitor musculoskeletal syndrome, reasons for treatment discontinuation and efficacy of interventions used. Aromatase inhibitor induced musculoskeletal syndrome was reported by 302 (82 %) of 370 respondents. Twenty-seven percent had discontinued treatment for any reason and of these, 68 % discontinued because of the musculoskeletal syndrome. Eighty-one percent had used at least one intervention from the following three categories to manage the syndrome: doctor prescribed medications, over-the-counter/complementary medicines or alternative/non-drug therapies. Anti-inflammatories, paracetamol (acetaminophen) and yoga were most successful in relieving symptoms in each of the respective categories. Almost a third of respondents reported that one or more interventions helped prevent aromatase inhibitor discontinuation. However, approximately 20 % of respondents found no intervention effective in any category. We conclude that aromatase inhibitor induced musculoskeletal syndrome is a significant issue for Australian women and is an important reason for treatment discontinuation. Women use a variety of interventions to manage this syndrome; however, their efficacy appears limited.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Turkey 1 1%
Unknown 97 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 17%
Student > Bachelor 8 8%
Researcher 7 7%
Student > Doctoral Student 7 7%
Unspecified 5 5%
Other 22 22%
Unknown 33 33%
Readers by discipline Count As %
Medicine and Dentistry 24 24%
Nursing and Health Professions 14 14%
Psychology 8 8%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Unspecified 5 5%
Other 11 11%
Unknown 32 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#4,858,395
of 23,866,543 outputs
Outputs from Supportive Care in Cancer
#1,159
of 4,774 outputs
Outputs of similar age
#64,176
of 285,484 outputs
Outputs of similar age from Supportive Care in Cancer
#23
of 84 outputs
Altmetric has tracked 23,866,543 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,774 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,484 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 84 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.